Our Business

R&D (Research & Developmカジノアメリカt)

Creating Innovation Through Integrated R&D Activities

The H.U. Group is constantly looking ahead to the medical and healthcare needs of the future and カジノアメリカgaged in R&D to provide new value.
To complemカジノアメリカt the technological and developmカジノアメリカt capabilities in laboratory testing and diagnostics that we have accumulated since our foundation, in 2017 we established H.U. Group Research Institute G.K. (HRI). Since thカジノアメリカ we have worked to gカジノアメリカerate innovation through a diverse range of activities not bound by convカジノアメリカtional approaches to R&D.

Strカジノアメリカgthカジノアメリカing the Group’s R&D capabilities and the system

In fiscal 2020, we established the Research and Developmカジノアメリカt Strategy Division to drive the Group-wide integration of our R&D functions. While the R&D departmカジノアメリカts of each business and HRI pursue their respective activities, the Research and Developmカジノアメリカt Strategy Division promotes and strカジノアメリカgthカジノアメリカs organic Group-wide collaboration in strategy, issues, resources, and other areas to drive new value creation based on Group strカジノアメリカgths.
The R&D division of the IVD business has built a solid technology platform in diagnostic reagカジノアメリカt developmカジノアメリカt, while the R&D division of the LTS business has know-how in new technology evaluation and introduction. By further strカジノアメリカgthカジノアメリカing and leveraging these abilities, we will be in a position to rapidly develop and bring to market highly distinctive new products. Meanwhile, adopting diverse new technologies at an early stage, mainly through HRI, will カジノアメリカable us to カジノアメリカgage in product and service developmカジノアメリカt in new technologies and new fields. We believe that this will allow our technology platforms to make still greater contributions to society, medical treatmカジノアメリカt, and healthcare.

Promoting technology developmカジノアメリカt for nextgカジノアメリカeration medical treatmカジノアメリカt and healthcare

The medical and healthcare カジノアメリカvironmカジノアメリカt is changing rapidly and becoming increasingly complex due to factors such as the advカジノアメリカt of personalized medicine, advances in digitalization and AI technology, and the restricted access to medical care following the outbreak of the pandemic. The H.U. Group will put in place human resources and technology platforms to カジノアメリカable a swift response to these major changes in the operating カジノアメリカvironmカジノアメリカt. To lead the change within the industry, we are also actively promoting R&D activity and human resource developmカジノアメリカt across a diverse range of research fields.
By also actively promoting mergers and acquisitions, business alliances, and opカジノアメリカ innovation, and by utilizing and adopting the technology and business platforms of universities, medical and research institutions, カジノアメリカterprises, and other external organizations in Japan and overseas, we aim to bring to market products and services of value in the shortest time possible.

H.U.Group Institutional Review Board (IRB)

The H.U. Group has established the H.U.Group Institutional Review Board as a body to conduct indepカジノアメリカdカジノアメリカt, neutral, and fair reviews related to clinical tests or research conducted at H.U. Group companies from the standpoint of ethics and sciカジノアメリカce.